All In Biotech

Drug Trial Radar · NCT06707610

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

234

Planned (sponsor's estimate)

Start

Feb 10, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.

Conditions

  • Advanced Cancer
  • Advanced Solid Tumor

Interventions

  • ALK202Drug

    Administered intravenously, once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of ALK202 in adult participants with advanced solid tumors; To determine the maximum tolerated dose (MTD); To determine the recommended dose(s) of ALK202 for subsequent clinical studies.Time frame: Approximately 36 months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • D&H Cancer Research Center Llc

    Margate, Florida · Recruiting

  • Next Oncology

    Fairfax, Virginia · Recruiting

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia · Recruiting

  • Macquarie University

    Sydney, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.